Inhibrx | Investors - News Releases

News Releases

Month Year

Month Year

Jun 15, 2026

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
May 14, 2026

Inhibrx Reports First Quarter 2026 Financial Results
May 11, 2026

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
May 8, 2026

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
Apr 21, 2026

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Apr 20, 2026

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Mar 19, 2026

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Mar 2, 2026

Inhibrx Announces Participation in Upcoming Scientific Conference
Dec 16, 2025

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Nov 14, 2025

Inhibrx Reports Third Quarter 2025 Financial Results
Nov 4, 2025

Inhibrx Announces Participation in Upcoming Scientific Conferences
Oct 23, 2025

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Oct 22, 2025

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Aug 13, 2025

Inhibrx Reports Second Quarter 2025 Financial Results
May 14, 2025

Inhibrx Reports First Quarter 2025 Financial Results
Apr 1, 2025

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
Mar 17, 2025

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Jan 21, 2025

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Jan 13, 2025

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
Nov 14, 2024

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
Nov 4, 2024

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
Aug 13, 2024

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
May 24, 2024

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
May 10, 2024

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
May 8, 2024

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
Feb 28, 2024

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Jan 23, 2024

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Nov 9, 2023

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Nov 2, 2023

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
Oct 18, 2023

Inhibrx Announces Participation in Upcoming Scientific Conferences
Aug 29, 2023

Inhibrx Announces $200 Million Private Placement Financing
Aug 7, 2023

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
May 30, 2023

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
May 8, 2023

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Mar 6, 2023

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Jan 4, 2023

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates
Nov 18, 2022

Inhibrx Announces Participation in Upcoming Investor Conference
Nov 16, 2022

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma
Nov 7, 2022

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Oct 20, 2022

Inhibrx Announces Participation in Upcoming Scientific Conferences
Aug 15, 2022

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma
Aug 8, 2022

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Jun 30, 2022

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance
May 19, 2022

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting
May 12, 2022

Inhibrx To Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency
May 9, 2022

Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Mar 24, 2022

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting
Feb 28, 2022

Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights
Feb 22, 2022

Inhibrx Announces Amended Loan Agreement with Oxford
Jan 4, 2022

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

- Two durable partial responses in checkpoint inhibitor-naive nasopharyngeal carcinoma and uveal melanoma patients in dose escalation of INBRX-106 in combination with Keytruda®

Show per page

Back To Top